TY - JOUR
T1 - HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients
AU - Berchtold, Lena
AU - Letouzé, Eric
AU - Alexander, Mariam Priya
AU - Canaud, Guillaume
AU - Logt, Anne-Els van de
AU - Hamilton, Patrick
AU - Mousson, Christiane
AU - Vuiblet, Vincent
AU - Moyer, Ann M
AU - Guibert, Sylvain
AU - Mrázová, Petra
AU - Levi, Charlène
AU - Dubois, Valérie
AU - Cruzado, Josep Maria
AU - Torres, Armando
AU - Gandhi, Manish J
AU - Yousfi, Nadhir
AU - Tesar, Vladimir
AU - Viklický, Ondrej
AU - Hourmant, Maryvonne
AU - Moulin, Bruno
AU - Rieu, Philippe
AU - Choukroun, Gabriel
AU - Legendre, Christophe
AU - Wetzels, Jack
AU - Brenchley, Paul
AU - Ballarín Castan, José Aurelio
AU - Debiec, Hanna
AU - Ronco, Pierre
N1 - Copyright © 2020. Published by Elsevier Inc.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Recurrence of primary membranous nephropathy after transplantation occurs in up to 44% of patients and is driven by PLA2R antibody. Here, we asked whether genetic determinants could improve risk prediction. First, we sequenced PLA2R1 and HLA-D loci in 248 patients with primary membranous nephropathy and identified two independent single nucleotide polymorphisms (SNPs) at risk for primary membranous nephropathy at each locus. These were rs9271188 (intergenic between HLA-DRB1 and HLA-DQA1,) and rs9275086 (intergenic between HLA-DQB1 and HLA-DQA2) at the HLA-D locus along with rs6726925 and rs13018963 at the PLA2R1 locus. Then, we investigated whether primary membranous nephropathy at-risk variants were associated with recurrence in a retrospective cohort of 105 donor-recipient pairs and a replication cohort of 40 pairs. Seven SNPs located between HLA-DRB1 and HLA-DQA1 in linkage disequilibrium with rs9271188, and three SNPs in the PLA2R1 region predicted recurrence when presented by the donor, but not when presented by the recipient. The two SNPs in the HLA-D region most strongly associated with recurrence (rs9271705 and rs9271550) were confirmed in the replication cohort. A genetic risk score based on the two best predictors at each locus (rs9271705, rs9271550, rs17830558, and rs3828323) identified a group of patients with high risk of recurrence. Thus, our results suggest that the graft contributes to recurrence of primary membranous nephropathy through the disease susceptibility HLA-D and PLA2R1 SNPs in an autoimmune milieu. Further studies are needed before implementation of the genetic testing in donor selection.
AB - Recurrence of primary membranous nephropathy after transplantation occurs in up to 44% of patients and is driven by PLA2R antibody. Here, we asked whether genetic determinants could improve risk prediction. First, we sequenced PLA2R1 and HLA-D loci in 248 patients with primary membranous nephropathy and identified two independent single nucleotide polymorphisms (SNPs) at risk for primary membranous nephropathy at each locus. These were rs9271188 (intergenic between HLA-DRB1 and HLA-DQA1,) and rs9275086 (intergenic between HLA-DQB1 and HLA-DQA2) at the HLA-D locus along with rs6726925 and rs13018963 at the PLA2R1 locus. Then, we investigated whether primary membranous nephropathy at-risk variants were associated with recurrence in a retrospective cohort of 105 donor-recipient pairs and a replication cohort of 40 pairs. Seven SNPs located between HLA-DRB1 and HLA-DQA1 in linkage disequilibrium with rs9271188, and three SNPs in the PLA2R1 region predicted recurrence when presented by the donor, but not when presented by the recipient. The two SNPs in the HLA-D region most strongly associated with recurrence (rs9271705 and rs9271550) were confirmed in the replication cohort. A genetic risk score based on the two best predictors at each locus (rs9271705, rs9271550, rs17830558, and rs3828323) identified a group of patients with high risk of recurrence. Thus, our results suggest that the graft contributes to recurrence of primary membranous nephropathy through the disease susceptibility HLA-D and PLA2R1 SNPs in an autoimmune milieu. Further studies are needed before implementation of the genetic testing in donor selection.
U2 - 10.1016/j.kint.2020.08.007
DO - 10.1016/j.kint.2020.08.007
M3 - Article
C2 - 32889013
SN - 0085-2538
JO - Kidney International
JF - Kidney International
ER -